
StockMarketNews.Today – Pfizer has not only underperformed the broader stock market, but its valuation is among the cheapest of some of the other big pharmaceuticals. Shares of Pfizer are trading at just 11.9 times 2019 earnings estimates, well below that of the S&P 500 and companies like Merck & Co. Inc.